Table 3.
Correlation between the expression of Nogo-B+ p-RhoA+ and the clinicopathologic features of NPC.
| All cases (n = 89) | Nogo-B+ p-RhoA+ expression | P-value | ||
|---|---|---|---|---|
| Low (n = 53) | High (n = 36) | |||
| Age (years) | 0.263 | |||
| <46 | 41 | 27 (50.9%) | 14 (38.9%) | |
| ≥46 | 48 | 26 (49.1%) | 22 (61.1%) | |
| Gender | 0.960 | |||
| Female | 22 | 13 (24.5%) | 9 (25.0%) | |
| Male | 67 | 40 (75.5%) | 27 (75.0%) | |
| T stage | 0.922 | |||
| T1-2 | 39 | 23 (43.4%) | 16 (44.4%) | |
| T3-4 | 50 | 30 (56.6%) | 20 (55.6%) | |
| N stage | 0.001* | |||
| N0-1 | 31 | 26 (49.1%) | 5 (13.9%) | |
| N2-3 | 58 | 27 (50.9%) | 31 (86.1%) | |
| M stage | 0.007a* | |||
| M0 | 81 | 52 (98.1%) | 29 (80.6%) | |
| M1 | 8 | 1 (1.90%) | 7 (19.4%) | |
| TNM stage (UICC/AJCC 8th edition, 2017) | 0.034* | |||
| I-II | 23 | 18 (34.0%) | 5 (13.9%) | |
| III-IV | 66 | 35 (66.0%) | 31 (86.1%) | |
| State | 0.002* | |||
| Survival | 73 | 49 (92.5%) | 24 (66.7%) | |
| Death | 16 | 4 (7.5%) | 12 (33.3%) | |
| Recurrent | 0.001* | |||
| No | 72 | 49 (92.5%) | 23 (63.9%) | |
| Yes | 17 | 4 (7.5%) | 13 (36.1%) | |
| Locoregional failure | 0.563a | |||
| No | 86 | 52 (98.1%) | 34 (94.4%) | |
| Yes | 3 | 1 (1.9%) | 2 (5.6%) | |
| Distant metastasis failure | 0.001* | |||
| No | 74 | 50 (94.3%) | 24 (66.7%) | |
| Yes | 15 | 3 (5.7%) | 12 (33.3%) | |
*p < 0.05
a Fisher’s exact test